IV Ketamine Therapy
Originally approved by the FDA in 1970 as an anesthetic, ketamine’s powerful antidepressant effects, when given at subanesthetic doses, were first discovered in the early 2000s by researchers at Yale.
It may be the most important discovery in psychiatry in the past fifty years. Ketamine therapy for depression began a revolution in how cognitive and mood disorders were treated.
Over 20 years later, dozens of peer-reviewed, well-controlled studies have demonstrated that IV Ketamine Therapy is highly efficacious in treating depression, suicidal ideation, PTSD, anxiety, OCD, and addiction/substance abuse disorders, even in patients who have not responded to conventional medication.
Over 20 years later, dozens of peer-reviewed, well-controlled studies have demonstrated that IV Ketamine Therapy is highly efficacious in treating depression, suicidal ideation, PTSD, anxiety, OCD, and addiction/substance abuse disorders, even in patients who have not responded to conventional medication.
IV Ketamine’s transformative potential
HOPE’s incoming Chief Medical Innovation Officer, David Feifel, MD, PhD, discusses how IV Ketamine has transformed treatment for depression by rapidly upregulating neuroplasticity during an interview with Dr Sanjay Gupta for CNN
Source: CNN
David Feifel, MD, PhD
His extensive knowledge and experience are embedded in the DNA of HOPE’s approach to ketamine therapy and neuroplastic medicine overall.